Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 290 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR “Nothing about us without us”: Why we’re working in partnership with... March 10, 2023 EMA Recommends Granting a Marketing Authorisation for Generic Dasatinib February 10, 2022 NF1 Associated with More Cancer Types Than Previously Known April 20, 2021 Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment... April 27, 2026 Load more HOT NEWS FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications Nivolumab/Ipilimumab Combination Should Precede Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated... Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe... What People in Asian American and Pacific Islander Communities Should Know...
